Effect of somatostatin combined with pantoprazole in treatment of liver cirrhosis with upper gastrointestinal hemorrhage

Gao ChengGuang; Xie Feng; Feng YaDong

doi:10.3969/j.issn.1001-5256.2016.02.017

Issue 2

Feb. 2016

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2016 > 32(2): 284-287

PDF( 213 KB)

Effect of somatostatin combined with pantoprazole in treatment of liver cirrhosis with upper gastrointestinal hemorrhage

DOI: 10.3969/j.issn.1001-5256.2016.02.017

Department of Internal Medicine,Jiangyan Hospital of Traditional Chinese Medicine

Received Date: 2015-10-09
Published Date: 2016-02-20

Abstract

Abstract

Objective To investigate the effect of somatostatin( SS) combined with pantoprazole in the treatment of liver cirrhosis with upper gastrointestinal hemorrhage( UGIH). Methods A total of 70 patients with liver cirrhosis and UGIH who were admitted to Jiangyan Hospital of Traditional Chinese Medicine from January 2011 to August 2015 were enrolled and randomized into combination group and control group,with 35 patients in each group. After admission,the patients in both groups were given conventional basic treatment; the patients in the combination group were given SS combined with pantoprazole,and those in the control group were given SS alone. The treatment outcome,time to hemostasis,volume of blood transfusion,48- hour rebleeding rate,length of hospital stay,and adverse events before and after treatment were observed and compared between the two groups. The t- test was applied for comparison of continuous data between groups,the chi- square test was applied for comparison of categorical data between groups,and the Wilcoxon rank sun test was applied for comparison of ranked data between groups. Results The combination group had a significantly better treatment outcome compared with the control group,with overall response rates of 94. 3% and 62. 9%,respectively( χ2= 10. 27,P < 0. 05); the marked response rate was60. 0% in the combination group and 34. 3% in the control group,and showed no significant difference between the two groups( χ2= 2. 80,P > 0. 05); the combination group had a significantly shorter time to hemostasis,a significantly lower volume of blood transfusion,and a significantly shorter length of hospital stay compared with the control group( t = 9. 036,6. 419,and 4. 186,all P < 0. 05); the combination group had a lower 48- hour rebleeding rate than the control group,but the 48- hour rebleeding rate showed no significant difference between the two groups( χ2= 0. 22,P > 0. 05); the incidence rate of adverse events was similar between the two groups and showed no significant difference( χ2= 0. 16,P > 0. 05),and the adverse events in both groups were mild. Conclusion SS combined with pantoprazole has better efficacy than SS alone in the treatment of liver cirrhosis with UGIH. Patients treated with SS combined with pantoprazole have a short time to hemostasis,a low volume of blood transfusion,a low rebleeding rate,and a short length of hospital stay,with no serious adverse events during treatment. The combination therapy is an effective treatment of liver cirrhosis with UGIH.
- liver cirrhosis,
- esophageal and gastric varices,
- somatostatin,proton pump inhibitors,

FullText(HTML)

References(17)

References

[1]WU JH,LIU XM,YANG JF,et al.Therapeutic effect of pituitrin combined with octreotide in cirrhotic patients with upper gastrointestinal bleeding:an analysis of 60 cases[J].J Qiqihar Uni Med,2013,34(10):1470-1471.(in Chinese)吴建辉,刘小梅,杨京帆,等.垂体后叶素联合奥曲肽治疗肝硬化上消化道出血60例疗效观察[J].齐齐哈尔医学院学报,2013,34(10):1470-1471.

[2]Chinese Society of Infectious Diseases and Parasitology,Chinese Society of Hepatology,Chinese Medical Association.Prevention and treatment of viral hepatitis[J].Chin J Infect Dis,2001,19(1):56-62.(in Chinese)中华医学会传染病与寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华传染病杂志,2001,19(1):56-62.

[3]LEE HY,LEE HJ,LEE SM,et al.A prospective randomized controlled clinical trial comparing the effects of somatostatin and vasopressin for control of acute vaficeal bleeding in the patients with liver cirrhosis[J].Korean J Intern Med,2003,18(3):161-166.

[4]CHONG H,WANG YZ.Clinical observation on somatostatin combined pantoprazole in treating sereve non-variceal upper gastrointestinal hemorrhage[J].Mod Med J China,2014,16(1):45-47.(in Chinese)常红,王银章.生长抑素联合泮托拉唑治疗非食管胃底静脉曲张性上消化道出血疗效观察[J].中国现代医药杂志,2014,16(1):45-47.

[5]ZHANG GP.Efficacy of somatostatin in treatment of liver cirrhosis complicated by upper gastrointestinal bleeding[J].J Baotou Med Coll,2012,28(6):62-63.(in Chinese)张广萍.生长抑素治疗肝硬化合并上消化道出血疗效观察[J].包头医学院学报,2012,28(6):62-63.

[6]DENG H,QI XS,GUO XZ.UK guidelines on the management of variceal haemorrhage in cirrhotic patients(2015):an excerpt of recommendatoins[J].J Clin Hopatol,2015,31(6):852-854.(in Chinese)邓晗,祁兴顺,郭晓钟.《2015年英国肝硬化静脉曲张出血防治指南》摘译[J].临床肝胆病杂志,2015,31(6):852-854.

[7] ZHAO Y.The curative effect of using omerazole and octreotide alone or jointly in treament of nanvariceal upper gastrointestinal bleeding[D].Shandong University,2011.(in Chinese)赵妍。奥美拉唑、奥曲肽单独与联合应用对非静脉曲张性上消化道出血的疗效[D].山东大学,2011.

[8]CHIU PW,SUNG JJ.Acute nonvafice upper gastrointestinal bleeding[J].Curr Opin Gastroenterol,2010,26(5):425-428.

[9]LIU JH,ZHU FF.Clinical efect observation of combination of octreotide and thrombin in the treatment of cirrhosis with upper gastrointestinal bleeding[J].J Bethune Med Sci,2014,12(1):21-23.(in Chinese)刘建华,朱芬芳.奥曲肽联合凝血酶治疗肝硬化合并上消化道出血疗效观察[J].白求恩医学杂志,2014,12(1):21-23.

[10]ZHAN Q,ZHENG KL,MU HJ.Serum angiotensini-converting enzyme levels and the therapeutic effects of octreotide in esophagcal variceal hemorrhage[J].Am J Med Sci,2011,342(1):20.

[11]LIU L.Analysis of clinical diagnosis and treatment of 48 cases of liver cirrhosis with upper gastrointestinal hemorrhage[J].J Tradit Chin Med Univ Hunan,2014,34(2):8-9.(in Chinese)刘亮.肝硬化并上消化道出血48例临床疗效分析[J].湖南中医药大学学报,2014,34(2):8-9.

[12]VITLIS Z,PAPP M,TORNAI I,et al.Prevention and treatment of esophageal variceal bleeding[J].Orv Hetil,2006,147(51):2455-2463.

[13]ZHANG ZY,ZHOU GW.Drug treatment of variceal bleeding due to portal hypertensio[J].J Abdominal Surg,2014,27(2):89-91.(in Chinese)张正筠,周光文.肝硬化门静脉高压症上消化道出血的药物防[J].腹部外科,2014,27(2):89-91.

[14]HUANG X,YANG L.Clinical observation of different doses of acetic octreotide in the treatment of esophagogastric varicose hemorrhage in patients with liver cirrhosis[J].China Pharm,2014,25(16):1478-1480.(in Chinese)黄欣,杨柳.不同剂量醋酸奥曲肽治疗肝硬化食管胃静脉曲张破裂出血的临床观察[J].中国药房,2014,25(16):1478-1480.

[15]JIANG HB.Clinical treatment of non-variceal upper gastrointestinal bleeding[J].Chin J Mod Drug Appl,2014,8(6):92-93.(in Chinese)姜海波.非静脉曲张性上消化道出血临床治疗观察[J].中国现代药物应用,2014,8(6):92-93.

[16]ZHANG JJ,DING J.The clinical application of octreotide combined with pantoprazole in gastrointestinal ulcer bleeding[J].J Dis Monitor Control,2013,7(8):474-475.(in Chinese)张京菊,丁晶.泮托拉唑联合奥曲肽在消化道溃疡合并出血中的临床应用[J].疾病监测与控制杂志,2013,7(8):474-475.

[17]LI JL,LIANG F,CAO Y.Clinical efficacy of octreotide combined with omeprazole in treatment of non-variceal upper gastrointestinal bleeding[J].Chin J Mod Drug Appl,2014,8(8):165-166.(in Chinese)李久伶,梁峰,曹颖.奥曲肽联合奥美拉唑治疗非曲张静脉上消化道大出血的临床分析[J].中国现代药物应用,2014,8(8):165-166.

Relative Articles

[1]	Zhuoga RENZENG, Kangjie YANG, Yongliang LU, Zhixin WANG, Haijiu WANG. Research advances in neutrophil extracellular traps and liver diseases[J]. Journal of Clinical Hepatology, 2024, 40(3): 639-643. doi: 10.12449/JCH240334
[2]	Mingqiang ZHU, Xing XIE, Qicheng LIAO, Xiao HE, Youming DING, Xiaohua WANG. Mechanism of cuproptosis and its role in liver diseases[J]. Journal of Clinical Hepatology, 2024, 40(11): 2332-2337. doi: 10.12449/JCH241131
[3]	Guiqiang WANG. Application and prospect of cell therapy in clinical treatment of liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(5): 1001-1003. doi: 10.3969/j.issn.1001-5256.2023.05.001
[4]	Zhuoran WANG, Bing ZHU, Limei YU, Shaoli YOU. Role of stem cell-derived exosomes in treatment of liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(3): 699-706. doi: 10.3969/j.issn.1001-5256.2023.03.034
[5]	Feiyan LI, Minggang WANG, Dewen MAO, Xiongbin GUI. Role of gasdermin D in the pathological progression of liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(3): 707-712. doi: 10.3969/j.issn.1001-5256.2023.03.035
[6]	Wenshang CHEN, Jijin ZHU, Shilai LI. Role of thymic stromal lymphopoietin in liver diseases[J]. Journal of Clinical Hepatology, 2022, 38(5): 1175-1178. doi: 10.3969/j.issn.1001-5256.2022.05.042
[7]	Weiyu CHEN, Faming SHU, Han WANG, Yanggang CAO, Jin HU, Dewen MAO. Role of the cytochrome P450 family in metabolic-associated liver diseases[J]. Journal of Clinical Hepatology, 2022, 38(9): 2182-2187. doi: 10.3969/j.issn.1001-5256.2022.09.045
[8]	Rui CHEN, Zhixin WANG, Haining FAN, Haijiu WANG. Research advances in the role of lymphocyte activation gene-3 in liver-related diseases[J]. Journal of Clinical Hepatology, 2021, 37(4): 977-981. doi: 10.3969/j.issn.1001-5256.2021.04.056
[9]	Lihui ZHANG, Minghao LIU, Wenxia ZHAO. Role of lipotoxicity in the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(2): 463-466. doi: 10.3969/j.issn.1001-5256.2021.02.045
[10]	Feiyu ZHANG, ADILA·Yakepu, Jinming ZHAO, Yanhang GAO. Mechanism of ferroptosis and its role in liver diseases[J]. Journal of Clinical Hepatology, 2021, 37(6): 1454-1458. doi: 10.3969/j.issn.1001-5256.2021.06.049
[11]	XU LiJun, AN XiuQin, LI Yue, LIU JinChun. Research advances in the role of myeloid-derived suppressor cells in liver diseases[J]. Journal of Clinical Hepatology, 2020, 36(12): 2851-2855. doi: 10.3969/j.issn.1001-5256.2020.12.045
[12]	XIAO WeiSong, LE YingYu, ZENG ShengLan, TAN XiaoBin, WU Cong, YA ChengYu, MAO DeWen. Role of pyroptosis in liver diseases[J]. Journal of Clinical Hepatology, 2020, 36(12): 2847-2850. doi: 10.3969/j.issn.1001-5256.2020.12.044
[13]	Wang ShaSha, Hua Fang, Jiao YongGeng, Qin ErYun, Zhi YiXiao, Pang MengYuan, Xu HongQin, Chi XiuMei, Niu JunQi, Hua Rui. Serum level of ceruloplasmin in patients with different liver diseases in Jilin,China[J]. Journal of Clinical Hepatology, 2020, 36(9): 2025-2029. doi: 10.3969/j.issn.1001-5256.2020.09.023
[14]	Chen ShuRu, Chong YuTian, Li XinHua. Pathogenic mechanism and clinical diagnosis of hereditary abnormal copper metabolism[J]. Journal of Clinical Hepatology, 2019, 35(8): 1667-1672. doi: 10.3969/j.issn.1001-5256.2019.08.003
[15]	Yu PengFei, Wu Qiao, Duan ZhongPing, Chen Yu. Research advances in the mechanism of drug-induced liver injury due to paracetamol[J]. Journal of Clinical Hepatology, 2019, 35(9): 2108-2112. doi: 10.3969/j.issn.1001-5256.2019.09.050
[16]	Chen Xiang, Wen DiGuang, You Yu, Gong JianPing. Role and mechanism of ferroptosis in treatment of liver cancer with sorafenib[J]. Journal of Clinical Hepatology, 2019, 35(10): 2316-2319. doi: 10.3969/j.issn.1001-5256.2019.10.040
[17]	Bao SuXia, Zheng JianMing, Shi GuangFeng. Research progress in association between interleukin-23 and liver diseases[J]. Journal of Clinical Hepatology, 2016, 32(2): 393-396. doi: 10.3969/j.issn.1001-5256.2016.02.044
[18]	Lu: XinPing, Wu Jing, Chen JingTao. Application of antibody preparation technology based on single B lymphocytes in liver diseases[J]. Journal of Clinical Hepatology, 2015, 31(12): 2104-2109. doi: 10.3969/j.issn.1001-5256.2015.12.028
[19]	Huang LanYu, Xu LieMing. Relationship between liver diseases and autophagy[J]. Journal of Clinical Hepatology, 2014, 30(2): 186-188. doi: 10.3969/j.issn.1001-5256.2014.02.022
[20]	Liu GuoWang, Cao WuKui. Application of stem cells in liver disease treatment[J]. Journal of Clinical Hepatology, 2011, 27(9): 999-1002.

Supplements(0)

Cited By

Cited by

Periodical cited type(4)

1.	郭新华，王佳慧，段雪琳，彭岳，赵铁建，郑洋，赵斌. 金属离子代谢：慢性肝病中医药防治新思路. 临床肝胆病杂志. 2024(07): 1498-1504 . 本站查看
2.	董昌君，张先林. 铜死亡在肝细胞癌发病机制中的研究进展. 中国普通外科杂志. 2024(07): 1172-1179 .
3.	刘诗卉，李冬冬，张宏坤，刘传苗，吴执竞，赵文. 细胞死亡在NAFLD发生发展中的研究进展. 齐齐哈尔医学院学报. 2024(16): 1578-1582 .
4.	朱明强，谢星，廖启成，何晓，丁佑铭，王小华. 铜死亡的发生机制及在肝脏疾病中的作用. 临床肝胆病杂志. 2024(11): 2332-2337 . 本站查看

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (463) PDF downloads(263)

Effect of somatostatin combined with pantoprazole in treatment of liver cirrhosis with upper gastrointestinal hemorrhage

DOI: 10.3969/j.issn.1001-5256.2016.02.017